TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria Stage/grade 1 or stage/ grade 2 hypertension, MSSBP ≥ 140 mm Hg, and/ or MSDBP ≥ 90 mm Hg, at Visit 1 and 2 in untreated patients Or Patients who are currently treated on monotherapy and uncontrolled and have a blood pressure ≤ 160/100 mm Hg at Visit 1 and Visit 2~Exclusion criteria Current treatment with a CCB MSSBP ≥ 180 mm Hg or MSDBP ≥ 110 mm Hg at any time between visit 1 and Visit 2 History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures Evidence of a secondary form of hypertension Cerebrovascular accident or myocardial infarction during the last 12 months, prior to Visit 1 Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug~2. Stable metformin therapy of at least 1500 mg/day, or less if that is a maximum tolerated dose.~3. HbA1c at screening 6.5% to 9.0% for patients on metformin and one other antidiabetic drug, and HbA1c \>7.0% to 10% for patients on metformin only~4. HbA1c \>7.0% to 10.0% at Visit 2 (Start of Run-in)~5. Age \>=18 and \<80years~6. Body Mass Index (BMI) \<=40 kg/m2~7. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation~Exclusion Criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent~2. Impaired hepatic function~3. Renal insufficiency or impaired renal function~4. Diseases of the central nervous system or psychiatric disorders or clinically relevant neurological disorders that may interfere with participation in the trial~5. Chronic or clinically relevant acute infections~6. Current or chronic urogenital tract infection~7. History of clinically relevant allergy/hypersensitivity~8. Treatment with glitazones (e.g., rosiglitazone, pioglitazone), glucagon-like peptide (GLP-1) analogues, or insulin within 3 months prior to informed consent~9. Treatment with anti-obesity drugs within 3 months prior to informed consent~10. Treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent~11. Alcohol abuse or drug abuse~12. Treatment with an investigational drug within 2 months prior to informed consent~13. Women of child-bearing potential who are nursing or pregnant, or who are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to periodic pregnancy testing during participation in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 60 or older (M/F)~2. Evidence of mild parkinsonian signs (incl. slow gait (\< 1m/s))~Exclusion Criteria:~1. Presence of clinically significant degenerative joint disease and/or neuropathy interfering with proper assessment of the motor UPDRS exam.~2. Presence of significant dementia.~3. Evidence of a large vessel stroke in a clinically relevant area (cerebral cortex, basal ganglia, thalamus) or mass lesion on structural brain imaging (MRI).~4. Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant.~5. Severe claustrophobia precluding neuroimaging procedures.~6. Hypersensitivity to the carbidopa, levodopa, and tablet components.~7. Any other medical history determined by investigators to preclude safe participation.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doripenem in the Treatment of Hospital-Acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized for \>= 48 hours or those with prior hospital admission of at least 48 hours who were discharged within the last 48 hours.~Exclusion Criteria:~* Hospital-acquired pneumonia known at the time of enrollment to be caused by pathogen(s) resistant to certain antibiotics~* Any rapidly progressing disease or immediately life-threatening illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I/IIa Study of FIXFc in Hemophilia B Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Are previously treated (PTPs) with severe (\<2 IU/dL endogenous FIX level) hemophilia B and at least 150 prior documented exposure days to other FIX products.~2. Have no prior history of or currently detectable inhibitor defined as \> 0.6 Bethesda units by the local lab. A family history of inhibitors will not exclude the patient.~3. No prior history of an allergic reaction or anaphylaxis associated with any FIX or IVIG administration.~4. No concurrent autoimmune disease.~5. At least 7 days since their last dose of FIX (wash-out period).~6. Certain laboratory testing criteria and other protocol-defined criteria may apply.~7. HIV negative or if HIV positive with a CD4 count ≥ 200 cells/mm3. HIV patients are allowed to receive protease inhibitors per the discretion of the Investigator.~Key Exclusion Criteria:~1. Presence of a major bleeding episode on Day 1 of study.~2. Any coagulation disorder in addition to hemophilia B.~3. A patient currently on a dose and regimen of FIX that would preclude participation in the study due to possible increased risk of bleeding because of the requirement to withhold treatment during the study period.~4. A positive d-dimer at screening.~5. Documented history of liver cirrhosis.~6. Positive for HBsAg and/or positive for hepatitis C antibody, and/or HIV positive with an ALT or AST greater than 5 times upper limit of normal.~7. Certain prior illnesses and other protocol-defined criteria.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rFIXFc (Type: EXPERIMENTAL): Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria AD:~* Male or female \>=50 years of age~* Meet National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS) criteria for probable AD with MMSE score of 10-24~Inclusion Criteria MCI:~* Male or female \>=50 years of age~* Have a Clinical Dementia Rating (CDR) of 0.5~* MMSE \>24~Normal subjects:~* Male or female \>=50 years of age~* MMSE \>=29~* Normal on psychometric test battery at screening~* Provide informed consent~Exclusion Criteria:~* Have a history or current diagnosis of other neurologic disease~* Have had or currently have a diagnosis of other neurodegenerative disease~* Have participated in experimental therapy targeted to amyloid plaque

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AD subjects (Type: EXPERIMENTAL): None
- MCI Subjects (Type: EXPERIMENTAL): MCI (mild cognitive impairment)
- Healthy controls (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Education in Adherence on Acne (PEAce)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects age of 12 years or older,~2. With facial acne vulgaris that can be managed in primary care~Exclusion Criteria:~1. Female subjects who are pregnant, nursing or planning a pregnancy during the study,~2. Subjects have a very severe variant of acne such as fulminating acne with systemic symptoms (acne fulminans)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care + supplementary education (Type: EXPERIMENTAL): Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
- Standard of care (Type: EXPERIMENTAL): Subjects will receive standard-of-care instructions only.
- Standard of care + additional visits (Type: EXPERIMENTAL): Subjects will receive standard-of-care instructions, and two additional clinical visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis~* Patients with a relapsing-remitting disease course~* Patients with EDSS score of 0-5.5~Exclusion Criteria:~* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc.~* Pregnant or nursing women~Other protocol-defined inclusion/exclusion criteria applied to this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod 1.25 mg (Type: EXPERIMENTAL): None
- Fingolimod 0.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia;~* Platelet count of less than 30×109/L at enrolment~* Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation.~* 18 years older.~Exclusion Criteria:~* Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus)~* congestive heart failure~* severe arrhythmia~* nursing or pregnant women~* aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria~* creatinine or serum bilirubin levels each 1•5 times or more than the normal range~* active or previous malignancy~* Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All-trans retinoic acid ＆Danazol (Type: EXPERIMENTAL): Danazol 400mg po and ATRA 10mg bid po
- Danazol (Type: ACTIVE_COMPARATOR): Danazol 400mg po

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* No concomitant medication~* BMI \< 25 kg/m2~* Age: 18-60 years old~Exclusion Criteria:~* Impaired glucose tolerance or diabetes mellitus~* Hyperthyroidism, hypothyroidism~* Hepatic, renal or cardiovascular diseases~* Malignancies~* History of medical therapy within 3 weeks prior to enrolment into the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin or ADH deficiency)~* termination of surgical or radiation treatment of pituitary tumors at least six month before study entry~* BMI of 20 - 39.9 kg/m2~* non-smoking status.~Exclusion Criteria:~* history of cardiovascular or pulmonary diseases~* current thyroxin dosage \> 1.6 µg/kg bw~* pregnancy~* epilepsy~* cerebrovascular diseases~* nodular goiter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women at least 36 weeks gestation requiring cervical ripening and induction of labor~Exclusion Criteria:~* No uterine scar (no previous delivery by cesarean section)~* No multiple gestation~* No condition that disallows use of prostaglandins for induction of labor~* No more than 3 previous vaginal births beyond 24 weeks gestation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVI 100 (Type: EXPERIMENTAL): Misoprostol vaginal insert 100 mcg over 24h
- MVI 50 (Type: EXPERIMENTAL): Misoprostol vaginal insert 50 mcg over 24h
- Cervidil 10 mg vaginal insert (Type: ACTIVE_COMPARATOR): Cervidil 10 mg over 24h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine and Propofol on Cerebral Blood Flow and Brain Oxygenation During Deep Brain Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III.~* Scheduled for DBS.~Exclusion Criteria:~* History of dystonia.~* Severe heart failure with ejection fraction less than 30%.~* History of obstructive sleep apnea.~* History of renal failure with creatinine level \> 2 mg/dl.~* Allergies to α-2 agonists and propofol.~* Current use of α-2 agonist medications such as clonidine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- propofol (Type: ACTIVE_COMPARATOR): Subjects will be sedated with propofol.
- dexmedetomidine (Type: ACTIVE_COMPARATOR): Subjects will be sedated with dexmedetomidine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Self-Management on Improving Sleep Apnea Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of obstructive sleep apnea~* No previous use of CPAP~* Must be a Veteran with residence within San Diego County~Exclusion Criteria:~* Home oxygen therapy~* Fatal comorbidities (i.e., life expectancy less than 6 mos)~* Contraindications for CPAP use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: PLACEBO_COMPARATOR): Usual sleep apnea and cpap care
- Self-Management (Type: EXPERIMENTAL): sleep apnea self-management program - 4 sessions, group-based

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIGH Altitude CArdiovascular REsearch in the ANDES

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent residence at low (\<500 m) altitude~* Conventional systolic BP (average of two measurements) 140-159 mmHg or conventional diastolic BP 90-99 mmHg in subjects untreated or after 4 weeks of washout~* Mean daytime systolic BP ≥135 and \<150 mmHg and/or mean daytime diastolic BP ≥85 and \<95 mmHg in subjects untreated or after 4 weeks of washout~* Written informed consent to participate in the study~Exclusion Criteria:~* Conventional systolic BP (average of two measurements) ≥150 mmHg and conventional diastolic BP ≥95 mmHg in treated subjects~* Regular use of two or more antihypertensive drugs (with the exception of subjects on two antihypertensive drugs in low doses)~* Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)~* Contraindications (including a history of adverse reactions) to angiotensin receptor blockers or calcium antagonists~* History of serious mountain sickness~* Subjects who over 3 months preceding inclusion in the study spent considerable (\> 1 week) amount of time at altitudes above 2500 m.~* Cardiovascular diseases other than hypertension (coronary heart disease, heart failure, atrial fibrillation, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)~* Suspected or confirmed secondary hypertension~* Diabetes mellitus~* Serious respiratory disorders~* Other conditions deemed relevant by the investigator (including liver disease, renal disease, thyroid disorders)~* BMI ≥35 kg/m2~* Upper arm circumference \>32 cm~* known severe obstructive sleep apnea (apnea-hypopnea index \> 30 or use of CPAP) or excessive daytime sleepiness (Epworth Sleepiness Scale \> 10)~* Pregnancy~* Premenopausal women not using effective contraceptive methods~* Elevated probability of noncompliance with the study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan/nifedipine (Type: EXPERIMENTAL): Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
- Placebo (Type: PLACEBO_COMPARATOR): Two tablets containing placebo daily in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete